TY - JOUR T1 - Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 937 LP - 942 DO - 10.1111/j.1525-1438.2007.01158.x VL - 18 IS - 5 AU - M. Takano AU - T. Sugiyama AU - N. Yaegashi AU - M. Sakuma AU - M. Suzuki AU - Y. Saga AU - K. Kuzuya AU - J. Kigawa AU - M. Shimada AU - H. Tsuda AU - T. Moriya AU - A. Yoshizaki AU - T. Kita AU - Y. Kikuchi Y1 - 2008/08/01 UR - http://ijgc.bmj.com/content/18/5/937.abstract N2 - Clear cell carcinoma (CCC) of the ovary has been recognized to show resistance to anticancer agents in the first-line chemotherapy. Our aim was to evaluate the effect of second-line chemotherapy in a retrospective study. A total of 75 patients diagnosed with CCC and treated between 1992 and 2002 in collaborating hospitals were reviewed. Criteria for the patients' enrollment were 1) diagnosis of pure-type CCC at the initial operation, 2) treatment after one systemic postoperative chemotherapy, 3) measurable recurrent or refractory tumor, 4) at least two cycles of second-line chemotherapy and assessable for the response, and 5) adequate clinical information. Regimens of first-line chemotherapy were conventional platinum-based therapy in 33 cases, paclitaxel plus platinum in 24 cases, irinotecan plus platinum in 9 cases, and irinotecan plus mitomycin C in 7 cases. Treatment-free periods were more than 6 months in 24 cases (group A) and less than 6 months in 51 cases (group B). In group A, response was observed in two cases (8%): one with conventional platinum therapy and another with irinotecan plus platinum. In group B, three cases (6%) responded: two with platinum plus etoposide and one case with irinotecan plus platinum. Median overall survival was 16 months in group A and 7 months in group B (P= 0.04). These findings suggest recurrent or resistant CCC is extremely chemoresistant, and there is only small benefit of long treatment-free period in CCC patients. Another strategy including molecular-targeting therapy is warranted for the treatment of recurrent or refractory CCC. ER -